It used to be that the only time I really saw mushrooms was when a few white button mushrooms appeared on a garden salad or atop my cheese pizza.
Psychedelics
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
MINDCURE's new Director is a veteran of capital markets.
Mindset Pharma Added to North American Psychedelics Index
Toronto, Ontario-- Mindset Pharma Inc., a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-based index provider, Solactive.
MINDCURE’s Psychedelics R&D Targets Blockbuster TBI Treatment Market
MINDCURE's R&D on traumatic brain injury (TBI) targets the LARGEST individual market for psychedelic drugs.
Vermont Lawmakers Prepare Psychedelics And Broader Drug Decriminalization Bills For Introduction
Vermont lawmakers plan to introduce at least two bills this legislative session to decriminalize the possession of drugs, with one of those proposals expected early next week.
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
California bill would decriminalize psychedelics, paving the way for medical treatment
A California lawmaker has introduced legislation that would decriminalize psychedelics in the state, the latest bold step in a movement to end America’s war on drugs.
Can LSD cure our pandemic anxiety? MindMed is spending big to find out
While many people will look back on the pandemic as a dark time, it has also spurred some positive developments—most notably in the field of drug development, where miraculous breakthroughs like mRNA vaccines are transforming immunology.
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first line of mushroom-based nootropics now available for sale.
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
U.S. Psychedelic Drug Legalization: Urgency or Inertia?
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Transatlantic Capital, Inc. Announces Plan To Initiate Early Phases of Cannabis and Psilocybin Production in the Aftermath of Their Most Recent Land Acquisition
PORTLAND, OR / ACCESSWIRE / February 16, 2021 / Transatlantic Capital Inc. (OTC PINK:TACI) announces their plan to begin early stages of mass Cannabis and Psilocybin Mushroom production by early 2021. As mentioned in a previous announcement from October 22nd, 2020, Transatlantic Inc., or "TACI" finalized a land deal that gave them over 250 acres of rural property in Clarendon, Jamaica which will allow them to safely produce and manufacture their medicinal products.
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE adds bioinformatics to its drug development platform.
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
Why psychedelics are a more ‘compassionate’ way to treat trauma
THE PAST DECADE has been witness to a renaissance in psychedelics research.